Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
=== Function in plants === Plants require magnesium to synthesize chlorophyll, essential for photosynthesis. Magnesium in the center of the porphyrin ring in chlorophyll functions in a manner similar to the iron in the center of the porphyrin ring in heme. Magnesium deficiency in plants causes late-season yellowing between leaf veins, especially in older leaves, and can be corrected by either applying epsom salts (which is rapidly leached), or crushed dolomitic limestone, to the soil.
=== Pharmacokinetics === Peak levels of tavapadon are reached after approximately 2 to 4 hours with oral administration. It shows dose-proportional pharmacokinetics across its maintenance dosage range. Food does not significantly modify the pharmacokinetics of tavapadon and it can be taken without regard for food. The volume of distribution of tavapadon is 63.5 L. Its plasma protein binding is 93%, primarily to albumin. Tavapadon is primarily metabolized by CYP3A4. It has a major inactive metabolite. Unchanged tavapadon is excreted less than 1% in urine and feces. Its major inactive metabolite was excreted less than 5% in urine and feces. The elimination half-life of tavapadon is 25.5 hours.
In 2021, Schmitt led a lawsuit against the Biden administration challenging COVID-19 vaccine requirements for health care workers. In 2021, Schmitt challenged the administration's decision to suspend new oil and gas leases on federal land and water. In 2021, Schmitt and 13 other Republican state attorneys general sued to block an executive order directing federal agencies to consider the social costs of emissions of greenhouse gases (carbon, methane and nitrous oxide) in regulatory cost-benefit analyses. In 2021, Schmitt and 21 other Republican attorneys general sued the Biden administration over Biden's revocation of the permit for the Keystone XL Pipeline. In 2022, Schmitt and Jeff Landry of Louisiana sued the federal government, claiming it was censoring anti-vaccine activism on social media. In 2024, the Supreme Court in Murthy v. Missouri rejected the case due to the plaintiffs' lack of standing. In the decision, Justice Amy Coney Barrett found no evidence of government coercion and wrote that plaintiffs could not "manufacture standing" based on hypothetical or self-inflicted harm. In 2022, Schmitt and 21 other Republican state attorneys general sued the Biden administration over a program that prohibits discrimination based on sexual orientation and gender identity in schools that receive federal funds. In September 2022, Schmitt joined a lawsuit on behalf of the Higher Education Loan Authority of the State of Missouri to block the administration's executive order on student debt relief.
=== Antibiotics === Physicians often prescribe the antibiotic trimethoprim-sulfamethoxazole to prevent bacterial infections. This drug also has the benefit of sparing the normal bacteria of the digestive tract. Fungal infection is commonly prevented with itraconazole, although a newer drug of the same type called voriconazole may be more effective. The use of this drug for this purpose is still under scientific investigation.
Sources: en.wikipedia.org
The molecular mechanism behind the formation of these tumors is not well understood, likely due to their low prevalence. Currently, no mutations have been identified in association with thyrotroph adenomas. In the presence of other pituitary tumors, the thyrotropic cells are unaffected.
Thus tr is roughly proportional to F. The separation of particle bands X and Y, represented by the finite increment ∆tr in their retention times, is achieved only if the force increment ∆F between them is sufficient. A differential in force of only 10−16 N is required for this to be the case. The magnitude of F and ∆F depend on particle properties, field strength and the type of field. This allows for variations and adaptations of the technique. From this basic principle many forms of FFF have evolved varying by the nature of the separative force applied and the range in molecule size to which they are targeted.
The affinity of metal ions for ligands is described by a stability constant, also called the formation constant, and is represented by the symbol Kf. It is the equilibrium constant for its assembly from the constituent metal and ligands, and can be calculated accordingly, as in the following example for a simple case:
=== Pharmacokinetics === Aceclidine, when administered ophthalmically, is absorbed primarily through the conjunctival and corneal tissues. Its onset of action is rapid due to efficient local absorption. Systemically, aceclidine undergoes limited metabolism, as its primary site of effect is the eye, thereby minimizing significant systemic exposure. Distribution following ocular administration is predominantly localized, with low risk of systemic accumulation. Excretion details are not extensively characterized, but, like other topical miotic agents, aceclidine is presumed to have minimal systemic bioavailability and is likely eliminated primarily via the local ocular route and normal metabolic pathways.
Gabe Logan Newell (born November 3, 1962), known by his nickname Gaben, is an American video game developer and businessman who is the co-founder and president of the video game company Valve. Newell was born in Aspen, Colorado, and grew up in Davis, California. He attended Harvard University in the early 1980s but dropped out to join Microsoft, where he helped create the first versions of the Windows operating system. He also led development on a port of the game Doom for Windows 95. In 1996, Newell and Mike Harrington left Microsoft to found Valve and fund the development of their first game, Half-Life (1998). After the success of Half-Life, Harrington sold his stake in Valve to Newell and left in 2000. Newell led development of Valve's digital distribution service, Steam, which launched in 2003 and controlled most of the market for downloaded PC games by 2011. Forbes estimated that Newell owned at least half of Valve as of 2025. He is also the owner of the marine research organization Inkfish, the neuroscience company Starfish Neuroscience, and the custom yacht manufacturer Oceanco. Newell has been estimated as one of the wealthiest people in the United States and the wealthiest person in the video games industry, with an estimated net worth of $11 billion as of 2025.
Sources: en.wikipedia.org
It was realised that both hypocalcin and teleocalcin are the same. It was conclusively shown that the isolated compound was the factor that reduces calcium level in these fishes. In 1990, the exact chemical composition and biosynthesis war worked out, and was given the name "stanniocalcin" as it was found to be exclusively produced by the corpuscles of Stannius. The complete amino acid sequence was described in 1995.
=== 1. FC Lokomotive (1966–1990) === East German football went through a general reorganization in 1965, creating football clubs as centres of high-level football, during which the football department of SC Leipzig was separated from the sports club and reformed into football club 1. FC Lokomotive Leipzig, while rival Chemie Leipzig continued as a Betriebssportgemeinschaft (BSG), or corporate team. Like most East German clubs, it was assigned to a publicly owned enterprise as its "sponsor". In the case of Lokomotive, the providing enterprise was Deutsche Reichsbahn—the East German state railways—hence the name. The club's fortunes improved somewhat as they almost always finished well up the league table, but they were unable to win the top honour in the DDR-Oberliga, with losing final appearances in 1967, 1986, and 1988. Lok earned a clutch of East German Cups (FDGB Pokal) with victories in 1976, 1981, 1986, and 1987, against failed appearances in the Cup final in 1970, 1973, and 1977. They also won the UEFA Intertoto Cup in 1966 and made an appearance in the 1987 final of the European Cup Winners' Cup, falling 0–1 to Johan Cruyff's Ajax after a Marco van Basten goal.
Iron-pyrite FeS2 represents the prototype compound of the crystallographic pyrite structure. The structure is cubic and was among the first crystal structures solved by X-ray diffraction. It belongs to the crystallographic space group Pa3 and is denoted by the Strukturbericht notation C2. Under thermodynamic standard conditions the lattice constant
Type I and II β turns exhibit a relationship to one another because they potentially interconvert by the process of peptide plane flipping (180° rotation of the CONH peptide plane with little positional alteration to side chains and surrounding peptides). The same relationship exists between type I' and II' β turns. Some evidence has indicated that these interconversions occur in beta turns in proteins such that crystal or NMR structures merely provide a snapshot of β turns that are, in reality, interchanging. In proteins in general all four beta turn types occur frequently but I is most common, followed by II, I' and II' in that order. Beta turns are especially common at the loop ends of beta hairpins; they have a different distribution of types from the others; type I' is the most common, followed by types II', I and II. Additional turn types have been defined by clustering turn conformations within very high-resolution protein structures. Asx turns and ST turns resemble beta turns except that residue i is replaced by the side chain of an aspartate, asparagine, serine or threonine. The main chain–main chain hydrogen bond is replaced by a side chain–main chain hydrogen bond. 3D computer superimposition shows that, in proteins, they occur as one of the same four types that beta turns do, except that their relative frequency of occurrence differs: type II' is the most common, followed by types I, II and I'.
Single-walled carbon nanotubes (SWCNTs) and multi-walled carbon nanotubes (MWCNTs) are efficient in enhancing the amplification of long PCR. Carbon nanopowder (CNP) can improve the efficiency of repeated PCR and long PCR, while zinc oxide, titanium dioxide and Ag NPs were found to increase the PCR yield. Previous data indicated that non-metallic NPs retained acceptable amplification fidelity. Given that many NPs are capable of enhancing PCR efficiency, it is clear that there is likely to be great potential for nanoPCR technology improvements and product development. Nested PCR: increases the specificity of DNA amplification, by reducing background due to non-specific amplification of DNA. Two sets of primers are used in two successive PCRs. In the first reaction, one pair of primers is used to generate DNA products, which besides the intended target, may still consist of non-specifically amplified DNA fragments. The product(s) are then used in a second PCR with a set of primers whose binding sites are completely or partially different from and located 3' of each of the primers used in the first reaction. Nested PCR is often more successful in specifically amplifying long DNA fragments than conventional PCR, but it requires more detailed knowledge of the target sequences. Overlap-extension PCR or Splicing by overlap extension (SOEing) : a genetic engineering technique that is used to splice together two or more DNA fragments that contain complementary sequences.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.